Decoding health through molecular insight.

Aitiologic is a precision medicine startup providing multi-modal liquid biopsy solutions for early disease detection and targeted therapy.

Platform

Technology foundation and first applications.

We are building the first multi-modal liquid biopsy platform to decode genomic, epigenomic, and fragmentomic cfDNA signals at single-molecule resolution from a simple blood draw.

Technology

aitios® Platform

Foundational multi-modal liquid biopsy platform for tissue-resolved cfDNA signal interpretation.

Explore

Application

aitios® NIPPT

First-trimester Non-Invasive Prenatal and Preeclampsia Testing for early risk stratification.

Explore

Updates

Latest news and events.

Preprint

First-Trimester Multi-modal cfDNA Analysis for Prediction of Preterm and Term Preeclampsia

First-trimester multi-modal, tissue-resolved cfDNA analysis enables early risk stratification across the full clinical spectrum of preeclampsia from a single routine blood sample.

Read on medRxiv

Upcoming event

bio:cap Europe

Jun 9-11, 2026 | Berlin, Germany

Meet us at bio:cap Europe in Berlin for focused conversations with investors, industry partners, and founders working across biotechnology, TechBio, diagnostics, and AI.

Meet us

Dec 6, 2025

Aitiologic Takes on Preeclampsia: Preparing for Large-Scale Validation after Presentation of Feasibility Study at FMF Conference in London

Aitiologic's Chief Medical Officer, Dr. Rebecca Ertl, presented the first feasibility results of the aitios® platform for tissue-specific liquid biopsy to over 1,500 clinicians and researchers.

Open article

Oct 4, 2024

Aitiologic developing liquid biopsy platform assay for tissue-of-origin analysis, early disease detection

Precision medicine startup Aitiologic is developing a liquid biopsy assay and analysis platform that hopes to enable early disease detection by harnessing both the genetic and epigenetic signatures of cell-free DNA from blood samples.

Read on GenomeWeb

Network & Development Partners